The human toll of COVID-19 has demonstrated the necessity – and difficulty – of quickly identifying emerging respiratory diseases. Lab-based diagnostic tests have played an important role during the pandemic. But from the viewpoint of quality of care and clinical management, timely infection control, and the ability to act upon results, the future will likely belong to portable, CLIA-waived rapid diagnostic tests.
Point-of-care tests (POCTs) are performed at the site of sample collection (e.g., bedside, physician's office or emergency department) and provide results usually in less than two hours and in some cases, within 10 minutes. They require little hands-on time and no specific laboratory training, as most critical steps are automated in a single device. Perhaps most important, they promptly identify the causative pathogen and help the healthcare professional choose the appropriate treatment or make the right decisions in outbreak situations, such as hospitalization or quarantine.
“CLIA-waived” tests refer to those that the U.S. Food and Drug Administration has determined to be simple and that present “an insignificant risk of erroneous result.” (A list of tests granted waived status under CLIA may be found here.) Physician office labs wishing to perform CLIA-waived tests must first apply for a CLIA Certificate of Waiver, and then ensure that those performing tests follow the manufacturers’ instructions.
For some time, point-of-care tests have allowed healthcare professionals to identify whether an infectious agent is viral or bacterial. That’s important, because antibiotics are only needed for treating certain infections caused by bacteria. Respiratory tract infections are a significant contributor to the global burden of respiratory tract illnesses, with up to 4 million deaths worldwide in 2013. Several pathogens, including viruses and bacteria, can cause respiratory tract infections. As clinical presentations often overlap, identification of the underlying pathogen based solely on clinical criteria is challenging
While some respiratory viruses -- such as influenza A virus (IAV) or human respiratory syncytial virus (RSV) -- are well-known and circulate worldwide, previously unknown or rare infectious diseases are spreading rapidly. They include human bocavirus (HBoV), human coronaviruses (HCoV-HKU1, -NL63), human metapneumovirus (HMPV), rhinovirus type C (RV-C), and human polyomaviruses (KIPyV, WUPyV), as well as SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), novel strains of influenza virus A and B, and, most recently, SARS coronavirus 2 (SARS-CoV-2).
New and innovative diagnostic techniques, ranging from biosensors to novel portable and current lab-based nucleic acid amplification methods, offer a look at next-generation POCTs. While prototypes for some methods already exist, others are still experimental.
A key criterion for the evaluation of future POCTs will be their ability to identify the origin of the patient's symptoms, and to distinguish relevant pathogen(s) from bystander pathogens. Questions need to be answered about the correct timing of diagnostic testing with regard to a patient's course of illness. The sensitivity and predictive value of a diagnostic test depend on:
Advances in diagnostic capabilities may change the way we identify, document, and communicate respiratory viral infections. In the future, patients will increasingly demand to know the responsible pathogen and their clinical prognosis. As researchers develop pathogen-specific antiviral therapies and vaccines, new diagnostic algorithms will be needed to ensure the highest quality of care while containing costs.
With worldwide manufacturing facilities and an international sales and distribution network, Sekisui Diagnostics is a solid partner for healthcare professionals and distributors around the world. Among its offerings are a line of CLIA-waived point-of-care tests to help identify influenza virus A and B, including Acucy® Influenza A&B, OSOM® Ultra Flu A&B Test, OSOM® Ultra Plus Flu A&B Test, and Silaris® Influenza A&B Test.